October 28, 2025 | Press Release
Test demonstrates 89% sensitivity for detection of preclinical stage I/II high grade serous ovarian cancer at 98% specificity in average risk postmenopausal women WALTHAM, Mass., October 28, 2025 /PRNewswire/ – Mercy BioAnalytics, Inc., a pioneer in blood-based...September 3, 2025 | Press Release
WALTHAM, Mass., September 3, 2025 /PRNewswire/ – Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the closing of a $59 million series B financing. The round was co-led by...July 8, 2025 | Press Release
WALTHAM, Mass., June 8, 2025 /PRNewswire/ – Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of Prasanth Reddy, M.D. MPH, FACP, as its Chief Medical Officer. Dr.... 
September 30, 2024 | Press Release
Publications describe foundational technology and the verification of the Mercy Halo™ ovarian cancer screening test WALTHAM, Mass., Sept 30, 2024 /PRNewswire/ — The Journal of Molecular Diagnostics has published two companion papers describing a novel technology...June 25, 2024 | Press Release
Mercy selected as one of three finalists for Disruptive Technology Award Competition WALTHAM, Mass., June 24, 2024 /PRNewswire/ — Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, has been...May 29, 2024 | Press Release
WALTHAM, Mass., May 29, 2024 /PRNewswire/ — Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for...